About: PSA response following the 'steroid switch' in patients with castration-resistant prostate cancer treated with abiraterone: A case report

Facets (new session)
Description
Metadata
Settings
- owl:sameAs
- Inference Rule:

About: PSA response following the 'steroid switch' in patients with castration-resistant prostate cancer treated with abiraterone: A case report Goto Sponge NotDistinct Permalink

An Entity of Type : wikibase:Item, within Data Space : wikidata.demo.openlinksw.com associated with source document(s)

Attributes	Values
rdf:type	Item
description	wetenschappelijk artikel (nl) im Oktober 2018 veröffentlichter wissenschaftlicher Artikel (de) наукова стаття, опублікована в жовтні 2018 (uk)
publication date	wds:Q57105398-CB7E3298-E394-480D-AA58-0D12B8FD923A
publication date	2018-10-01 00:00:00Z (xsd:dateTime)
language of work or name	wds:Q57105398-299D38BB-2E57-43E7-AA63-11079BA3CB5D
language of work or name	English
cites work	wds:Q57105398-0089CA47-D578-4C7E-8B15-FE5F7405E3A9 wds:Q57105398-0A1E5872-B797-4F2A-9F83-6A217414EF10 wds:Q57105398-0A88CEDA-490B-4851-B6AC-2900B842C07C wds:Q57105398-0DF6EE2D-8F87-4426-8497-F9447E613D8B wds:Q57105398-0FF32F53-78E9-4C5F-A3CB-0656F4EF56F9 wds:Q57105398-26675008-9043-4F77-A83E-3A3C5B452E12 wds:Q57105398-2902E73D-3CBC-45E1-9EFD-3199DD846029 wds:Q57105398-32CB773A-1FEF-4149-BAF5-BE4238783F6C wds:Q57105398-33BCB1D5-0F1D-4541-A24F-4709AE0C27F7 wds:Q57105398-408708F5-2A26-4DEB-B1E3-02EA9519ED60 wds:Q57105398-47E82BAA-18A4-4AA8-8E93-72DB54866D21 wds:Q57105398-551E4923-8B81-46EA-95CE-232E0B08762C wds:Q57105398-6BBF5B2B-E4AD-447D-B20B-4D7E9DDB5526 wds:Q57105398-6DBDB6C3-3EC9-40DB-AC12-627357DF122C wds:Q57105398-74E97A57-A036-4781-9A3F-0D176667715C wds:Q57105398-8171EAA5-F2B3-4F73-8E02-2B6EE8A58CF1 wds:Q57105398-8C0E6B5B-ABBD-403C-AA03-6C59609086D8 wds:Q57105398-966D79EF-0BCD-470C-ACA9-7B040CF9252F wds:Q57105398-ADCF8F6A-D2EC-49A7-8900-94FFBBA7FC92 wds:Q57105398-AF011B23-DF08-479C-A908-A0B4FB21326C wds:Q57105398-BD6D329B-A3AF-4DD3-93E8-701A105A3B7A wds:Q57105398-C9F37A8C-9B12-45DD-95E7-B2C25222DE83 wds:Q57105398-D5EB0761-B260-4C77-A6CF-7890CA7C1B55 wds:Q57105398-D90754FC-C477-420D-8CCB-B1E96441113E wds:Q57105398-E83274E0-FAA8-4058-ADF3-2C72046DE6C4 wds:Q57105398-E8717820-FB77-425D-80AD-B555C891D136 wds:Q57105398-EE89F9CE-96F6-42E1-8A08-D86BB62283C7 wds:Q57105398-F687DD84-D1BA-448B-8073-18D65C72DE97 wds:Q57105398-F99002E8-3D66-4FCD-A74C-0F81E4ACAC0B wds:Q57105398-FE1A322C-9F8D-40BE-8F85-D56365C66D8D
cites work	Glucocorticoids can promote androgen-independent growth of prostate cancer cells through a mutated androgen receptor Treatment of metastatic prostatic cancer with low-dose prednisone: evaluation of pain and quality of life as pragmatic indices of response Activation of the androgen receptor N-terminal domain by interleukin-6 via MAPK and STAT3 signal transduction pathways Abiraterone and increased survival in metastatic prostate cancer Mutation of the androgen-receptor gene in metastatic androgen-independent prostate cancer Secondary hormonal therapy for advanced prostate cancer Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer Interactions of abiraterone, eplerenone, and prednisolone with wild-type and mutant androgen receptor: a rationale for increasing abiraterone exposure or combining with MDV3100. Glucocorticoid receptor confers resistance to antiandrogens by bypassing androgen receptor blockade Addition of docetaxel, zoledronic acid, or both to first-line long-term hormone therapy in prostate cancer (STAMPEDE): survival results from an adaptive, multiarm, multistage, platform randomised controlled trial Binding of Steroids to Mineralocorticoid Receptors: Implications for in Vivo Occupancy by Glucocorticoids* Dexamethasone does not significantly contribute to the response rate of docetaxel and estramustine in androgen independent prostate cancer Potential mechanism for the effects of dexamethasone on growth of androgen-independent prostate cancer. The role of corticosteroids in the treatment of pain in cancer patients Low doses of oral dexamethasone for hormone-refractory prostate carcinoma Putting the brakes on continued androgen receptor signaling in castration-resistant prostate cancer Tumour responses following a steroid switch from prednisone to dexamethasone in castration-resistant prostate cancer patients progressing on abiraterone Practical Guidance on the Role of Corticosteroids in the Treatment of Metastatic Castration-resistant Prostate Cancer Corticosteroid-induced inhibition of adrenal androgen production in selected patients with prostate cancer Glucocorticoids suppress tumor angiogenesis and in vivo growth of prostate cancer cells. Efficacy of low-dose dexamethasone in castration-refractory prostate cancer A randomised phase 2 trial of dexamethasone versus prednisolone in castration-resistant prostate cancer Pharmacodynamics and pharmacokinetics of synthetic mineralocorticoids and glucocorticoids: receptor transactivation and prereceptor metabolism by 11beta-hydroxysteroid-dehydrogenases. Androgen Receptor-Dependent and -Independent Mechanisms Involved in Prostate Cancer Therapy Resistance. Possible mechanism of dexamethasone therapy for prostate cancer: Suppression of circulating level of interleukin‐6 Abiraterone plus Prednisone in Metastatic, Castration-Sensitive Prostate Cancer Oral low-dose dexamethasone for androgen-independent prostate cancer patients Differential expression of determinants of glucocorticoid sensitivity in androgen-dependent and androgen-independent human prostate cancer cell lines WOMEN IN CANCER THEMATIC REVIEW: New roles for nuclear receptors in prostate cancer Abiraterone--what is wrong with the adrenal glands?
author name string	wds:Q57105398-0423D6BD-D394-4E70-93DC-4F8A946D07F8 wds:Q57105398-061BA403-FBE7-4013-975D-CD0EBDFE2083 wds:Q57105398-0FD19003-3430-4D4E-AD58-6ED5A4C2AF25 wds:Q57105398-2612CB42-00DF-4768-8A02-A5E773DCEACB wds:Q57105398-4318E31B-9FC5-4DAA-AC29-019889AFC4B9 wds:Q57105398-435A32A9-DC44-4591-9C53-3EA25AB87BF7 wds:Q57105398-4BBCA1F8-F1B7-4802-8C79-81766D1E1956 wds:Q57105398-6ED05E59-101A-43A7-AC8D-5D7BB39E0E80 wds:Q57105398-95EDF7C6-3B36-4431-89FF-46F39D1B8D16 wds:Q57105398-D343C7F3-B90A-41AB-B2B5-7B28C92F4DFC wds:Q57105398-F422D810-5A84-43AA-9C79-80C7BA0B0854
author name string	Akira Komiya Hiroshi Masuda Kazuto Yamazaki Tomonori Kato Kotaro Otsuka Satoko Kojima Yukio Naya Ayumi Fujimoto Kazuhiro Araki Kyokushin Hou Takahito Suyama
rdfs:label	PSA response following the 'steroid switch' in patients with castration-resistant prostate cancer treated with abiraterone: A case report (en) PSA response following the 'steroid switch' in patients with castration-resistant prostate cancer treated with abiraterone: A case report (nl)
skos:prefLabel	PSA response following the 'steroid switch' in patients with castration-resistant prostate cancer treated with abiraterone: A case report (en) PSA response following the 'steroid switch' in patients with castration-resistant prostate cancer treated with abiraterone: A case report (nl)
name	PSA response following the 'steroid switch' in patients with castration-resistant prostate cancer treated with abiraterone: A case report (en) PSA response following the 'steroid switch' in patients with castration-resistant prostate cancer treated with abiraterone: A case report (nl)
title	wds:Q57105398-19430240-01DE-4460-9CD0-CCFC60806AEF
title	PSA response following the 'steroid switch' in patients with castration-resistant prostate cancer treated with abiraterone: A case report (en)
page(s)	wds:Q57105398-ACCF54A9-DC5A-4B28-8BAC-783F54AE6816
page(s)	5383-5388

Faceted Search & Find service v1.16.117 as of May 05 2024

Alternative Linked Data Documents: ODE Content Formats:

RDF

ODATA

Microdata

About

OpenLink Virtuoso version 07.20.3239 as of May 5 2024, on Linux (x86_64-centos_6-linux-gnu), Single-Server Edition (378 GB total memory, 183 GB memory in use)
Data on this page belongs to its respective rights holders.
Virtuoso Faceted Browser Copyright © 2009-2025 OpenLink Software